P-2 Modified GTX second-line therapy in pancreatic adenocarcinoma: An updated analysis

Abstract

To date, no standard of care for second-line therapy of advanced pancreatic adenocarcinoma has been established for patients progressing on first-line FOLFIRINOX or Gemzar/Abraxane. [1] The use of a modified regimen of Gemcitabine, Docetaxel, and Capecitabine (GTX) has been suggested following considerable evidence which showed GTX-induced synergistic apoptosis of human pancreatic cancer cells. [2] Retrospective analysis of GTX regimen use, previously conducted at our institution, has shown good tolerability in this patient population with a response rate of 33%.